The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
Recordati Rare Diseases Canada Inc. announced today the Canadian product availability of ISTURISA® (osilodrostat) for the treatment of adult patients with Cushing's disease who have persistent or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback